BDX seeks CE Mark for its Liverty TIPS Stent Graft, a next-gen device aimed at improving portal hypertension treatment and ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced application of ...
BD (Becton, Dickinson and Company) announced European CE Mark approval for the Liverty transjugular intrahepatic portosystemic sh ...
A new review highlights how combining multiple ultrasound techniques may help detect and assess portal hypertension in ...
Antivirals given for chronic hepatitis B include nucleos(t)ide analog monotherapy and pegylated interferon-alpha therapy, but ...
The Company will present new NAVIGATE trial analyses at EASL 2026 (May 27–30, 2026), including an oral presentation on reduced varices based on favorable changes in markers of fibrosis formation and ...
Franklin Lakes, New Jersey-based BD designed the stent graft to expand treatment options for patients with cirrhosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results